BioCentury
ARTICLE | Clinical News

AVN-211: Phase I started

March 16, 2009 7:00 AM UTC

Avineuro began a placebo-controlled, dose-escalation, European Phase I trial to evaluate 2 and 4 mg/day of oral AVN-211. ...